|
rs76863441
|
|
A |
0.760 |
GeneticVariation |
GWASCAT |
Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
|
28753643 |
2017 |
|
rs76863441
|
|
|
0.760 |
GeneticVariation |
BEFREE |
Causal risk ratios for coronary heart disease per 65% lower Lp-PLA<sub>2</sub> activity were: 0.95 (0.88-1.03) with Val279Phe; 0.92 (0.74-1.16) with carriage of any loss-of-function variant; 1.01 (0.68-1.51) with Val379Ala; and 0.95 (0.89-1.02) with darapladib treatment.
|
27940953 |
2017 |
|
rs76863441
|
|
|
0.760 |
GeneticVariation |
BEFREE |
RH + HH genotype, RH genotype, and H allele of R92H were significantly associated with an increased risk of CHD (P = 0.005, P = 0.009, and P = 0.003, respectively), while no associations were observed between V279F and I198T and CHD (A379V was not analyzed because of deviation from Hardy-Weinberg equilibrium).
|
25690150 |
2015 |
|
rs76863441
|
|
|
0.760 |
GeneticVariation |
BEFREE |
Carriage of the V279F null allele within the gene encoding Lp-PLA₂ is protective from coronary artery disease in South Korean males.
|
21490708 |
2011 |
|
rs76863441
|
|
|
0.760 |
GeneticVariation |
BEFREE |
These data suggested that the V279F polymorphism in LP-PLA2 gene may contribute to CHD development.
|
21107710 |
2011 |
|
rs76863441
|
|
|
0.760 |
GeneticVariation |
BEFREE |
The results indicate 92H allele had probably increased the risk of CHD, while the hypothesized effects of A379V and V279F polymorphisms on CHD cannot be confirmed in present data.
|
20926117 |
2010 |
|
rs76863441
|
|
|
0.760 |
GeneticVariation |
BEFREE |
Both single SNP analysis and haplotype analysis showed that the V279F and I198T polymorphisms were significantly associated with the reduced Lp-PLA(2) activity, but neither was associated with increased CHD risk.
|
19034521 |
2009 |
|
rs1051931
|
|
|
0.040 |
GeneticVariation |
BEFREE |
CHD risks were higher in carriers of homozygous mutant of rs1805017 and rs1805018 than those with wild-type homozygotes, OR (95% CI) were 1.45 (1.16-1.92) and 1.51 (1.23-1.97), respectively, but the other two SNPs, rs16874954 and rs1051931 were not significant associated with CHD risks.
|
29728838 |
2018 |
|
rs1805017
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Polymorphisms in rs1805017 and rs1805018, additional interaction between rs1805017 and smoking, and haplotype containing the rs1805017-H and rs1805018-T alleles were associated with increased CHD risk.
|
29728838 |
2018 |
|
rs1805018
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Polymorphisms in rs1805017 and rs1805018, additional interaction between rs1805017 and smoking, and haplotype containing the rs1805017-H and rs1805018</span>-T alleles were associated with increased CHD risk.
|
29728838 |
2018 |
|
rs1051931
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Causal risk ratios for coronary heart disease per 65% lower Lp-PLA<sub>2</sub> activity were: 0.95 (0.88-1.03) with Val279Phe; 0.92 (0.74-1.16) with carriage of any loss-of-function variant; 1.01 (0.68-1.51) with Val379Ala; and 0.95 (0.89-1.02) with darapladib treatment.
|
27940953 |
2017 |
|
rs1051931
|
|
|
0.040 |
GeneticVariation |
BEFREE |
RH + HH genotype, RH genotype, and H allele of R92H were significantly associated with an increased risk of CHD (P = 0.005, P = 0.009, and P = 0.003, respectively), while no associations were observed between V279F and I198T and CHD (A379V was not analyzed because of deviation from Hardy-Weinberg equilibrium).
|
25690150 |
2015 |
|
rs1805017
|
|
|
0.040 |
GeneticVariation |
BEFREE |
These findings indicated that R92H variant in PLA2G7 gene might contribute to CHD susceptibility in a southern Chinese population.
|
25690150 |
2015 |
|
rs1805018
|
|
|
0.040 |
GeneticVariation |
BEFREE |
RH + HH genotype, RH genotype, and H allele of R92H were significantly associated with an increased risk of CHD (P = 0.005, P = 0.009, and P = 0.003, respectively), while no associations were observed between V279F and I198T and CHD (A379V was not analyzed because of deviation from Hardy-Weinberg equilibrium).
|
25690150 |
2015 |
|
rs1805017
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The R92H polymorphism was highly related to the plasma PAF-AH levels and the risk of CHD, especially among patients with BSS, even with the adjustment for the effects of traditional factors.
|
25034894 |
2014 |
|
rs1805018
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The I198T polymorphism was highly associated with risk of CHD with BSS, but was associated with neither the risk of CHD with no BSS nor with elevated plasma PAF-AH levels.
|
25034894 |
2014 |
|
rs1051931
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The results indicate 92H allele had probably increased the risk of CHD, while the hypothesized effects of A379V and V279F polymorphisms on CHD cannot be confirmed in present data.
|
20926117 |
2010 |
|
rs1805017
|
|
|
0.040 |
GeneticVariation |
BEFREE |
14 association studies focusing on three polymorphisms (A379V, V279F and R92H) in PLA2G7 gene and risk of CHD were included in meta-analysis, covering a total of 8,280 cases and 5,656 controls.
|
20926117 |
2010 |
|
rs1805018
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Both single SNP analysis and haplotype analysis showed that the V279F and I198T polymorphisms were significantly associated with the reduced Lp-PLA(2) activity, but neither was associated with increased CHD risk.
|
19034521 |
2009 |
|
rs16874954
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CHD risks were higher in carriers of homozygous mutant of rs1805017 and rs1805018 than those with wild-type homozygotes, OR (95% CI) were 1.45 (1.16-1.92) and 1.51 (1.23-1.97), respectively, but the other two SNPs, rs16874954 and rs1051931 were not significant associated with CHD risks.
|
29728838 |
2018 |
|
rs9395208
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In conclusion, all the six inflammation-related CpG-SNPs (rs16944, rs2071008, rs12732361, rs2065666, rs9395208, and rs1800686) were associated with CHD in the combined or subgroup tests, suggesting an important role of inflammation in the risk of CHD.
|
27461004 |
2016 |